- Global Pharma News & Resources

Antivenom Drugs Market sieze would grow upto USD 1.35 billion by 2029

The first class Antivenom Drugs market report comprises of a complete analysis of the market with key players, applications, types, and regions. This global market report brings into light key market dynamics of the sector. It gives an in-depth knowledge on what the recent developments are, product launches are, while also keeping the track for recent acquisitions, mergers, joint ventures and competitive research in the global industry. It provides guidelines about planning of advertising and sales promotion efforts. The top notch Antivenom Drugs marketing report is a vital document in planning business objectives or goals.

The wide ranging Antivenom Drugs report is generated by performing high level market research analysis of key marketplace segments to identify opportunities, challenges, drivers, and market structures for clients. Strategically analyzed facts and figures of the market and keen business insights covered in this market report would be a key aspect in achieving enduring business growth. This market research report encompasses different industry verticals for Healthcare industry such as company profile, contact details of manufacturer, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company.

Get Sample Report + All Related Graphs & Charts @ 

Some of The Major Companies That Are Covered In This Report: Bioclone Institute (Mexico), Pfizer Inc (U.S.)., F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany)., Rare Disease Therapeutics, Inc. (U.S.), VINS Bioproducts Ltd (India), BTG International Inc (U.K.), Incepta Pharma (Bangladesh), Bharat Serums and Vaccines Limited (BSV) (India), Hamilton Company (U.S.), B. Braun SE (Germany), Cardinal Health (U.S.), BD (U.S.), Boston Scientific Corporation (U.S.), Alomone Labs (Israel), Wyeth, LLC (U.S.)

Data Bridge Market Research analyses a growth rate in the global antivenom drugs market in 2022-2029. The expected CAGR of global antivenom drugs market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 0.95 billion in 2021, and it would grow upto USD 1.35 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Antivenom drugs are used to treat venomous bites and stings, usually preferable in high-toxicity cases. Antivenin, venom antiserum, and antivenom immunoglobulin are the different other names of antivenom drugs. These medications can potentially reverse the effects of snake bites, and generally, an adequate therapeutic dose is injected. Additionally, these medications also help in kidney dialysis, artificial respiration, prosthesis as well as rehabilitation services.

It offers cautious encounters on the current and past examples of the business which rely upon the events that have occurred around here space and data accumulated from them. The archive further assesses the current business patterns which are needy upon the past data. Also, it offers data on key conditions, for example, the COVID-19 pandemic and its impact on the extensive length and passing impact on the business space.

This report covers the Global Antivenom Drugs Market and its development technology dynamics, financial situation, growth strategy, product portfolio, and forecast period. Do not miss out on the trading opportunities at Global Antivenom Drugs Market. Get key industry insights and help your business grow by talking to our analyst. The Global Antivenom Drugs Market report not only provided significant value to users, but also presented the market’s wide spectrum of opportunities and threats. Information gleaned from various business models, such as SWOT or PESTEL. The report additionally includes the industry size, share, creation volume, and utilization to acquire experiences about the governmental issues and tussle of dealing with an enormous piece of the portion of the overall industry.

Request For TOC @

The geographic regions and countries covered in the study include:

The major countries covered in the global antivenom drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America accounts for the largest market share due to the involvement of major drug suppliers, the region’s high spending on research and development, and healthcare and qualified professionals.

Asia-Pacific is projected to score the highest market growth rate due to increased research and innovations in the antivenom drugs market.

Inquiry before Buying the Report @


  • Increasing Drug Approvals

Approvals and launches of novel drugs in the leading regions are anticipated to be a major factor driving antivenom drugs market growth during the forecast period. For instance, in October 2018, Silanes Laboratories received U.S. FDA approval for Anavip, an antivenom against the bite of snakes of the Crotalus family, including the rattlesnake. In 2017, Rare Disease Therapeutics, Inc., partner of Silanes Laboratories, launched Anavip in the U.S. market. Thus, all these factors boost the growth of the market.

  • Higher Initiatives by Government and Private Organizations

To satisfy to the demand for antivenom drugs, several market players are opting for many initiatives to strengthen their market presence. For instance, in September 2021, a partnership was made between Papua New Guinea (PNG) and Australia to donate antivenoms and help save the lives of people bitten or stung by venomous snakes and marine creatures. It has been extended for a further two years, 2021-2023. This will provide the availability of antivenomous drugs across the countries, thus driving the market.


  • Rising Incidence of Snake Bites

According to the update by World Health Organization in May 2021, nearly 5.4 million snake bites occur each year, leading to up to 2.7 million envenomings (poisoning from snake bites) and around 81,000 to 138,000 deaths because of snake bites. Furthermore, it often leads to about three times as many amputations and other permanent disabilities. As per a research article “Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study,” published in July 2020, India witnessed approximately 1.2 million deaths due to snakebites between 2001-2019. Thus, these increasing cases demand higher antivenom drugs and are boosting the market’s growth.

  • Increasing Focus on Extension of Shelf Life

The major players in the market are focusing on increasing shelf life and extending the expiry date of their products. For instance, in September 2018, BTG plc. announced that the U.S. FDA has approved updating the shelf life of CroFab Crotalidae Polyvalent Immune Fab (Ovine) up to 60 months. In addition, in 2018, Pfizer, Inc. worked with the U.S. FDA to extend the expiration date of Antivenin’s Lot No. L67530 for an additional 12 months. Thus, all these efforts are having an impact on the growth of the market.

Recent Development

  • In July 2022, the foundation for Antivenom Research and Development Centre (AVRDC) was conducted at the Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru Helix Biotech Park, Electronics City to increase the production activities for antivenom.
  • In April 2022, the Complementary Agreement to the Technical Cooperation Agreement between Brazil and the Government of the Republic of the Union of Myanmar for the implementation of the project “Improving methodologies and techniques for the production of antivenom serum in Myanmar – phase II: antivenom quality” was signed. The aim of the project is to increase the quality and performance of the antivenom serum produced in that Asian country.

Global Antivenom Drugs Market

The global antivenom drugs market is segmented on the basis of type, treatment, animal, mode of action, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.


  • Monovalent
  • Polyvalent


  • Vaccines
  • Hyper Immune


  • Snakes
  • Spiders
  • Scorpions
  • Others

Mode of Action

  • Cytotoxic
  • Neurotoxic
  • Haemotoxic
  • Cardiotoxic
  • Myotoxic
  • Others

End User

  • Hospital/Clinical Laboratories
  • Physician Offices
  • Reference Laboratories
  • Others

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Other

Access Full Report:

Key questions answered in the report:

What will the market growth rate of Antivenom Drugs market in 2029?
What are the key factors driving the Antivenom Drugs market?
What are sales, revenue, and price analysis of top manufacturers of Antivenom Drugs market?
Who are the distributors, traders and dealers of Antivenom Drugs market?
Who are the key manufacturers in Antivenom Drugs market space?
What are the Antivenom Drugs market opportunities and threats faced by the vendors in the Antivenom Drugs market?
What are sales, revenue, and price analysis by types and applications of Antivenom Drugs market?
What are sales, revenue, and price analysis by regions of Antivenom Drugs market?
What are the market opportunities, market risk and market overview of the Antivenom Drugs market?

Top Trending Reports:

About Data Bridge Market Research:                         

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Editor Details

  • Company:
    • The Wire Times
Last Updated: 22-Nov-2022